Top

CNS Drugs

Published in:

01-06-2001 | Review Article

Combination Nicotine Replacement Therapy for Smoking Cessation

Rationale, Efficacy and Tolerability

Authors: Dr Christine T. Sweeney, Reginald V. Fant, Karl O. Fagerstrom, Joseph F. McGovern, Jack E. Henningfield

Published in: CNS Drugs | Issue 6/2001

Abstract

Currently available nicotine replacement therapy (NRT) medications provide effective treatment for tobacco dependence, typically doubling success rates compared with placebo. A strategy for further improving the efficacy of NRT is to combine one medication that allows for passive nicotine delivery (e.g. transdermal patch) with another medication that permits ad libitum nicotine delivery (e.g. gum, nasal spray, inhaler). The rationale for combining NRT medications is that smokers may need both a slow delivery system to achieve a constant concentration of nicotine to relieve cravings and tobacco withdrawal symptoms, as well as a faster acting preparation that can be administered on demand for immediate relief of breakthrough cravings and withdrawal symptoms.

This article reviews 5 published studies that have examined the effectiveness of combination NRT compared with monotherapy in providing withdrawal relief and smoking cessation, and examines other factors relevant to the promotion of combination NRT for treating tobacco dependence.

The data show that there are conditions under which combinations of NRT products provide greater efficacy in relieving withdrawal and enabling cessation than monotherapy, but the findings are not robust and additional research is warranted to better understand the magnitude and generality of the benefits of combination therapy. There are also regulatory and commercial obstacles that must be considered. Nonetheless, combination NRT has the potential to provide effective treatment of tobacco dependence in persons whose dependence is refractory to currently available treatments.

Centers for Disease Control. Smoking-attributable mortality and years of potential life lost-United States, 1984. MMWR Morb Mortal Wkly Rep 1997; 46: 444–51

Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, 2000 Jun

U.S. Department of Health and Human Services. Reducing tobacco use: a report of the surgeon general. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000

Royal College of Physicians. Nicotine addiction in Britain. A report of the tobacco advisory group of the royal college of physicians. London: Royal College of Physicians, 2000

West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 53Suppl. 5 (Pt 1): S1–S19

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: WHO, 1992

U.S. Department of Health and Human Services: the health benefits of smoking cessation, a report of the surgeon general. Washington, DC: U.S. Government Printing Office, 1990

Centers for Disease Control. Smoking cessation during previous year among adults — United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep 1993; 42: 504–7

10.

Centers for Disease Control. Cigarette smoking among adults — United States, 1998. MMWR Morb Mortal Wkly Rep 2000; 49: 881–4

11.

Benowitz NL, Porchet H, Sheiner L, et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44: 23–8PubMedCrossRef

12.

Schneider NG, Lunell E, Olmstead RE, et al. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 1996; 31: 65–80PubMedCrossRef

13.

Benowitz NL. Nicotine replacement therapy: what has been accomplished — can we do better? Drugs 1993; 45: 157–70PubMedCrossRef

14.

Butschky MF, Bailey D, Henningfield JE, et al. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 1995; 50: 91–6PubMedCrossRef

15.

Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196–203PubMedCrossRef

16.

Benowitz NL. Nicotine replacement therapy: what has been accomplished: can we do better? Drugs 1993; 45: 157–70PubMedCrossRef

17.

U.S. Department of Health and Human Services. The health consequences of smoking: nicotine addiction, a report of the surgeon general. Washington, DC: U.S. Government Printing Office, 1988

18.

Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. JAMA 1991; 22: 3133–8

19.

Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 1997; 5: 137–42PubMedCrossRef

20.

Shiffman S, Khayrallah M, Niaura R, et al. Efficacy of acute administration of Nicorette gum against cue-provoked craving [paper]. Presentation at the annual meeting of the Society for Research on Nicotine and Tobacco; 1998 Mar 26–29; New Orleans (LA)

21.

Fagerstrom KO. Combined use of nicotine replacement products. Health Values 1994; 18: 15–20

22.

Benowitz NL, editor. Nicotine safety and toxicity. New York (NY): Oxford University Press, 1998

23.

Benowitz NL, Zevin S, Jacob P. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 1998; 287: 958–62PubMed

24.

Benowitz NE. Summary: risks and benefits of nicotine. In: Benowitz NE, editor. Nicotine safety and toxicity. New York (NY): Oxford University Press, 1998: 89–97

25.

Windsor R, Oncken C, Henningfield J, et al. Behavioral and pharmacological treatment methods for pregnant smokers: issues for clinical practice. JAMA 2000; 55: 304–10

26.

Slotkin TA. The impact of fetal nicotine exposure on the nervous system development and its role in Sudden Infant Death Syndrome. In: Benowitz NE, editor. Nicotine safety and toxicity. New York (NY): Oxford University Press, 1998: 89–97

27.

Benowitz NL. Cardiovascular toxicity of nicotine: pharmacokinetic and pharmacodynamic considerations. In: Benowitz NE, editor. Nicotine safety and toxicity. New York (NY): Oxford University Press, 1998: 19–27

28.

Mahmarian JJ. Using nicotine patch therapy in patients with CAD: risks of smoking far outweigh risks of nicotine replacement. J Respir Dis 1998; 19: S13–S19

29.

Hurt RD, Croghan GA, Beede SD, et al. Nicotine patch therapy in 101 adolescent smokers. Arch Pediatr Adolesc Med 2000; 154: 31–7PubMed

30.

Smith TA, House Jr RF, Croghan IT, et al. Nicotine patch therapy in adolescent smokers. Pediatrics 1996; 98: 659–67PubMed

31.

Henningfield JE, Michaelides T, Sussman S. Developing treatment for tobacco addicted youth — issues and challenges. J Child Adolesc Subst Abuse 2000; 9: 5–26CrossRef

32.

Rennard SI, Daughton D, Windle J. Toxicity of nicotine replacement in patients with coronary heart disease. In: Benowitz NE, editor. Nicotine safety and toxicity. New York (NY): Oxford University Press, 1998: 49–53

33.

Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271–7PubMedCrossRef

34.

Leischow SJ, Valente SN, Hill AL, et al. Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol 1997; 5: 54–64PubMedCrossRef

35.

Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebocontrolled clinical trial. Prev Med 1995; 4: 41–7CrossRef

36.

Puska P, Korhonen HJ, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995; 4: 231–5CrossRef

37.

Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six yearfollow up. BMJ 1999; 318: 285–8PubMedCrossRef

38.

Sutherland, G. A placebo-controlled, double-blind combination trial of nicotine spray and patch [abstract]. Nicotine Tob Res 1999; 1(2): 186–7

39.

Bohandana AB, Nilsson F, Martinet Y. Nicotine inhaler and nicotine patch: A combination therapy for smoking cessation [abstract]. Nicotine Tob Res 1999; 1(2): 189

40.

Hughes JR. Treatment of nicotine dependence: is more better? JAMA 1995; 274: 1390–1PubMedCrossRef

41.

Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation. Nicotine Tob Res 1999; 1: 169–74PubMedCrossRef

42.

Killen JD, Fortmann SP, Davis L, et al. Do heavy smokers benefit from higher dose nicotine patch therapy. Exp Clin Psychopharmacol 1999; 7: 226–33PubMedCrossRef

43.

Schmitz JM, Schneider NG, Jarvik ME. Nicotine. In: Lowinson JH, Ruiz P, Millman RB, et al., editors. Substance abuse: a comprehensive textbook. 3rd ed. Baltimore (MD): Williams & Wilkins, 1997: 276–94

44.

Henningfield JE, Slade J. Tobacco dependence medications: Public health and regulatory issues. Food Drug Law J 1998; 53: 75–114PubMed

Title: Combination Nicotine Replacement Therapy for Smoking Cessation
Rationale, Efficacy and Tolerability
Authors: Dr Christine T. Sweeney
Reginald V. Fant
Karl O. Fagerstrom
Joseph F. McGovern
Jack E. Henningfield
Publication date: 01-06-2001
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 6/2001
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200115060-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Combination Nicotine Replacement Therapy for Smoking Cessation

Rationale, Efficacy and Tolerability

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2001

Methylphenidate (OROS® Formulation)

Aetiology and Treatment of Sleep Disturbances During Perimenopause and Postmenopause

Homocysteine Levels in Patients with Stroke

Methylphenidate (OROS® Formulation)

Methylphenidate (OROS® Formulation)

Brain and Spinal Cord Atrophy in Multiple Sclerosis